Michael Sundström takes key roles at Karolinska Development
This article was originally published in Scrip
Karolinska Development has appointed Michael Sundström vice-president of discovery research and CEO of Actar, a subsidiary of Karolinska Development, effective from 1 October 2011. Mr Sundström most recently served as managing director of Novo Nordisk Foundation Center for Protein Research.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.